Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 6Phase 3 5Phase 1 4

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 50NIH 18INDUSTRY 4NETWORK 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Glioblastoma 2Smoldering Multiple Myeloma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Advanced Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × sargramostim × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

NCT02149225 2018-08-07

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

Immatics Biotechnologies GmbH

Phase 1 Completed
16 enrolled
CNS

Glioblastoma

NCT02240537 2016-04-19

BBMPI03

Benovus Bio, Inc.

Phase 1 Unknown
4 enrolled
MyeloidOther hematologic neoplasmPlasma cell

Smoldering Multiple Myeloma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01403285 2014-05-19

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Immatics Biotechnologies GmbH

Phase 1 Terminated
6 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡